Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis
Previous studies have reported CD44 expression played an important role in the development and progression of tumor. The aim of study was to investigate whether single nucleotide polymorphisms (SNPs) of CD44 gene were associated with risk of non-small cell lung cancer (NSCLC), survival and occurrenc...
Gespeichert in:
| Veröffentlicht in: | Medical science monitor 2015-09, Vol.21, p.2694-2700 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2700 |
|---|---|
| container_issue | |
| container_start_page | 2694 |
| container_title | Medical science monitor |
| container_volume | 21 |
| creator | Liu, Yaosheng Qing, Haifeng Su, Xiuyun Wang, Cheng Li, Zhou Liu, Shubin |
| description | Previous studies have reported CD44 expression played an important role in the development and progression of tumor. The aim of study was to investigate whether single nucleotide polymorphisms (SNPs) of CD44 gene were associated with risk of non-small cell lung cancer (NSCLC), survival and occurrence rate of bone metastasis in patients with NSCLC.
A total of 234 patients with NSCLC between 2003 and 2010 were enrolled in this study and 468 healthy persons were used as controls. Two polymorphisms, rs13347 and rs187115, in the CD44 gene were genotyped using DNA from blood lymphocytes. For statistical analysis we used the chi-square test, Fisher's exact test, Kaplan-Meier method, and log-rank test.
CD44 gene rs13347 polymorphism was not associated with NSCLC risk. For rs187115, the association with NSCLC risk was observed (P |
| doi_str_mv | 10.12659/MSM.894357 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4573070</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1711537568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-931b44cde9fb50971bf462cea87c0b7e99aec93bb250df3bad7c6c17e82cf33c3</originalsourceid><addsrcrecordid>eNpVkVFLwzAUhYMobk6ffJc8CrKZNEnTvgiz6hQ2FafgW0jT1EXbZibtZP_ezk2ZELgh97vnhnMAOMZogIOQxeeT6WQQxZQwvgO6OKSkTzhDu1v3Djjw_h2hIAoR2wedICSsnURd8Dr03ioja2MraHOYXFEKR7rS8NEWy9K6-cz4En6ZeganjVuYhSxW3P00GSdQVhl8Mv5j9XJp26GJrqVvj_GHYC-XhddHm9oDLzfXz8ltf_wwukuG474iEa77McEppSrTcZ4yFHOc5jQMlJYRVyjlOo6lVjFJ04ChLCepzLgKFeY6ClROiCI9cLHWnTdpqTOlq9rJQsydKaVbCiuN-N-pzEy82YWgjBPEUStwuhFw9rPRvhal8UoXhay0bbzAHGPWmhhGLXq2RpWz3jud_63BSPxkIdosxDqLlj7Z_tkf-2s--QZ2wYVn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1711537568</pqid></control><display><type>article</type><title>Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Liu, Yaosheng ; Qing, Haifeng ; Su, Xiuyun ; Wang, Cheng ; Li, Zhou ; Liu, Shubin</creator><creatorcontrib>Liu, Yaosheng ; Qing, Haifeng ; Su, Xiuyun ; Wang, Cheng ; Li, Zhou ; Liu, Shubin</creatorcontrib><description>Previous studies have reported CD44 expression played an important role in the development and progression of tumor. The aim of study was to investigate whether single nucleotide polymorphisms (SNPs) of CD44 gene were associated with risk of non-small cell lung cancer (NSCLC), survival and occurrence rate of bone metastasis in patients with NSCLC.
A total of 234 patients with NSCLC between 2003 and 2010 were enrolled in this study and 468 healthy persons were used as controls. Two polymorphisms, rs13347 and rs187115, in the CD44 gene were genotyped using DNA from blood lymphocytes. For statistical analysis we used the chi-square test, Fisher's exact test, Kaplan-Meier method, and log-rank test.
CD44 gene rs13347 polymorphism was not associated with NSCLC risk. For rs187115, the association with NSCLC risk was observed (P<0.001). Allele G carriers had significantly higher occurrence rates of bone metastasis (OR=0.4, 95%CI: 0.20-0.64, P<0.001) and more advanced tumor stage (OR=2.6, 95%CI: 1.50-4.45, P=0.001) compared to carriers of allele A. The survival rates for patients with AA genotype were significantly higher than for patients with the AG+GG genotypes (P<0.001). In multivariate analysis of survival in NSCLC patients, significant predictors were CD44 gene (AG+GG) (RR=0.48, 95%CI: 0.34-0.68, P<0.001), tumor stage (RR=0.45, 95%CI: 0. 0.31-0.65, P<0.001), and bone metastasis (RR=1.52, 95%CI: 1.05-2.21, P=0.027).
CD44 gene rs187115 polymorphism is a potential predictive marker of survival in NSCLC patients, and is significantly correlated with bone metastasis and tumor stage.</description><identifier>ISSN: 1643-3750</identifier><identifier>ISSN: 1234-1010</identifier><identifier>EISSN: 1643-3750</identifier><identifier>DOI: 10.12659/MSM.894357</identifier><identifier>PMID: 26356590</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Aged ; Alleles ; Bone Neoplasms - genetics ; Bone Neoplasms - mortality ; Bone Neoplasms - secondary ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Clinical Research ; Female ; Genotype ; Humans ; Hyaluronan Receptors - genetics ; Kaplan-Meier Estimate ; Lung Neoplasms - genetics ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lymphocytes - cytology ; Male ; Middle Aged ; Neoplasm Metastasis ; Polymorphism, Single Nucleotide ; Prognosis ; Treatment Outcome</subject><ispartof>Medical science monitor, 2015-09, Vol.21, p.2694-2700</ispartof><rights>Med Sci Monit, 2015 2015</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-931b44cde9fb50971bf462cea87c0b7e99aec93bb250df3bad7c6c17e82cf33c3</citedby><cites>FETCH-LOGICAL-c381t-931b44cde9fb50971bf462cea87c0b7e99aec93bb250df3bad7c6c17e82cf33c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573070/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573070/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26356590$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Yaosheng</creatorcontrib><creatorcontrib>Qing, Haifeng</creatorcontrib><creatorcontrib>Su, Xiuyun</creatorcontrib><creatorcontrib>Wang, Cheng</creatorcontrib><creatorcontrib>Li, Zhou</creatorcontrib><creatorcontrib>Liu, Shubin</creatorcontrib><title>Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>Previous studies have reported CD44 expression played an important role in the development and progression of tumor. The aim of study was to investigate whether single nucleotide polymorphisms (SNPs) of CD44 gene were associated with risk of non-small cell lung cancer (NSCLC), survival and occurrence rate of bone metastasis in patients with NSCLC.
A total of 234 patients with NSCLC between 2003 and 2010 were enrolled in this study and 468 healthy persons were used as controls. Two polymorphisms, rs13347 and rs187115, in the CD44 gene were genotyped using DNA from blood lymphocytes. For statistical analysis we used the chi-square test, Fisher's exact test, Kaplan-Meier method, and log-rank test.
CD44 gene rs13347 polymorphism was not associated with NSCLC risk. For rs187115, the association with NSCLC risk was observed (P<0.001). Allele G carriers had significantly higher occurrence rates of bone metastasis (OR=0.4, 95%CI: 0.20-0.64, P<0.001) and more advanced tumor stage (OR=2.6, 95%CI: 1.50-4.45, P=0.001) compared to carriers of allele A. The survival rates for patients with AA genotype were significantly higher than for patients with the AG+GG genotypes (P<0.001). In multivariate analysis of survival in NSCLC patients, significant predictors were CD44 gene (AG+GG) (RR=0.48, 95%CI: 0.34-0.68, P<0.001), tumor stage (RR=0.45, 95%CI: 0. 0.31-0.65, P<0.001), and bone metastasis (RR=1.52, 95%CI: 1.05-2.21, P=0.027).
CD44 gene rs187115 polymorphism is a potential predictive marker of survival in NSCLC patients, and is significantly correlated with bone metastasis and tumor stage.</description><subject>Aged</subject><subject>Alleles</subject><subject>Bone Neoplasms - genetics</subject><subject>Bone Neoplasms - mortality</subject><subject>Bone Neoplasms - secondary</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Clinical Research</subject><subject>Female</subject><subject>Genotype</subject><subject>Humans</subject><subject>Hyaluronan Receptors - genetics</subject><subject>Kaplan-Meier Estimate</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lymphocytes - cytology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prognosis</subject><subject>Treatment Outcome</subject><issn>1643-3750</issn><issn>1234-1010</issn><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkVFLwzAUhYMobk6ffJc8CrKZNEnTvgiz6hQ2FafgW0jT1EXbZibtZP_ezk2ZELgh97vnhnMAOMZogIOQxeeT6WQQxZQwvgO6OKSkTzhDu1v3Djjw_h2hIAoR2wedICSsnURd8Dr03ioja2MraHOYXFEKR7rS8NEWy9K6-cz4En6ZeganjVuYhSxW3P00GSdQVhl8Mv5j9XJp26GJrqVvj_GHYC-XhddHm9oDLzfXz8ltf_wwukuG474iEa77McEppSrTcZ4yFHOc5jQMlJYRVyjlOo6lVjFJ04ChLCepzLgKFeY6ClROiCI9cLHWnTdpqTOlq9rJQsydKaVbCiuN-N-pzEy82YWgjBPEUStwuhFw9rPRvhal8UoXhay0bbzAHGPWmhhGLXq2RpWz3jud_63BSPxkIdosxDqLlj7Z_tkf-2s--QZ2wYVn</recordid><startdate>20150910</startdate><enddate>20150910</enddate><creator>Liu, Yaosheng</creator><creator>Qing, Haifeng</creator><creator>Su, Xiuyun</creator><creator>Wang, Cheng</creator><creator>Li, Zhou</creator><creator>Liu, Shubin</creator><general>International Scientific Literature, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150910</creationdate><title>Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis</title><author>Liu, Yaosheng ; Qing, Haifeng ; Su, Xiuyun ; Wang, Cheng ; Li, Zhou ; Liu, Shubin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-931b44cde9fb50971bf462cea87c0b7e99aec93bb250df3bad7c6c17e82cf33c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Alleles</topic><topic>Bone Neoplasms - genetics</topic><topic>Bone Neoplasms - mortality</topic><topic>Bone Neoplasms - secondary</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Clinical Research</topic><topic>Female</topic><topic>Genotype</topic><topic>Humans</topic><topic>Hyaluronan Receptors - genetics</topic><topic>Kaplan-Meier Estimate</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lymphocytes - cytology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prognosis</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Liu, Yaosheng</creatorcontrib><creatorcontrib>Qing, Haifeng</creatorcontrib><creatorcontrib>Su, Xiuyun</creatorcontrib><creatorcontrib>Wang, Cheng</creatorcontrib><creatorcontrib>Li, Zhou</creatorcontrib><creatorcontrib>Liu, Shubin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Yaosheng</au><au>Qing, Haifeng</au><au>Su, Xiuyun</au><au>Wang, Cheng</au><au>Li, Zhou</au><au>Liu, Shubin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2015-09-10</date><risdate>2015</risdate><volume>21</volume><spage>2694</spage><epage>2700</epage><pages>2694-2700</pages><issn>1643-3750</issn><issn>1234-1010</issn><eissn>1643-3750</eissn><abstract>Previous studies have reported CD44 expression played an important role in the development and progression of tumor. The aim of study was to investigate whether single nucleotide polymorphisms (SNPs) of CD44 gene were associated with risk of non-small cell lung cancer (NSCLC), survival and occurrence rate of bone metastasis in patients with NSCLC.
A total of 234 patients with NSCLC between 2003 and 2010 were enrolled in this study and 468 healthy persons were used as controls. Two polymorphisms, rs13347 and rs187115, in the CD44 gene were genotyped using DNA from blood lymphocytes. For statistical analysis we used the chi-square test, Fisher's exact test, Kaplan-Meier method, and log-rank test.
CD44 gene rs13347 polymorphism was not associated with NSCLC risk. For rs187115, the association with NSCLC risk was observed (P<0.001). Allele G carriers had significantly higher occurrence rates of bone metastasis (OR=0.4, 95%CI: 0.20-0.64, P<0.001) and more advanced tumor stage (OR=2.6, 95%CI: 1.50-4.45, P=0.001) compared to carriers of allele A. The survival rates for patients with AA genotype were significantly higher than for patients with the AG+GG genotypes (P<0.001). In multivariate analysis of survival in NSCLC patients, significant predictors were CD44 gene (AG+GG) (RR=0.48, 95%CI: 0.34-0.68, P<0.001), tumor stage (RR=0.45, 95%CI: 0. 0.31-0.65, P<0.001), and bone metastasis (RR=1.52, 95%CI: 1.05-2.21, P=0.027).
CD44 gene rs187115 polymorphism is a potential predictive marker of survival in NSCLC patients, and is significantly correlated with bone metastasis and tumor stage.</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>26356590</pmid><doi>10.12659/MSM.894357</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1643-3750 |
| ispartof | Medical science monitor, 2015-09, Vol.21, p.2694-2700 |
| issn | 1643-3750 1234-1010 1643-3750 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4573070 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Aged Alleles Bone Neoplasms - genetics Bone Neoplasms - mortality Bone Neoplasms - secondary Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Clinical Research Female Genotype Humans Hyaluronan Receptors - genetics Kaplan-Meier Estimate Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - pathology Lymphocytes - cytology Male Middle Aged Neoplasm Metastasis Polymorphism, Single Nucleotide Prognosis Treatment Outcome |
| title | Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A08%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20CD44%20Gene%20Polymorphism%20with%20Survival%20of%20NSCLC%20and%20Risk%20of%20Bone%20Metastasis&rft.jtitle=Medical%20science%20monitor&rft.au=Liu,%20Yaosheng&rft.date=2015-09-10&rft.volume=21&rft.spage=2694&rft.epage=2700&rft.pages=2694-2700&rft.issn=1643-3750&rft.eissn=1643-3750&rft_id=info:doi/10.12659/MSM.894357&rft_dat=%3Cproquest_pubme%3E1711537568%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1711537568&rft_id=info:pmid/26356590&rfr_iscdi=true |